IRIS
DE LORENZO, CLAUDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.102
NA - Nord America 4.646
EU - Europa 3.614
SA - Sud America 621
AF - Africa 151
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.139
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.460
SG - Singapore 2.129
RU - Federazione Russa 1.677
VN - Vietnam 1.068
CN - Cina 990
IT - Italia 670
BR - Brasile 488
HK - Hong Kong 394
DE - Germania 263
FR - Francia 176
FI - Finlandia 154
NL - Olanda 142
IE - Irlanda 111
JP - Giappone 107
GB - Regno Unito 104
CA - Canada 103
UA - Ucraina 100
IN - India 99
SE - Svezia 68
BD - Bangladesh 55
MX - Messico 52
CI - Costa d'Avorio 50
KR - Corea 48
PL - Polonia 44
AR - Argentina 43
ZA - Sudafrica 40
AT - Austria 28
IQ - Iraq 28
PH - Filippine 28
EC - Ecuador 27
ES - Italia 24
TR - Turchia 20
TH - Thailandia 19
ID - Indonesia 15
TW - Taiwan 15
CO - Colombia 14
PK - Pakistan 14
VE - Venezuela 13
PY - Paraguay 12
CL - Cile 9
LT - Lituania 9
MA - Marocco 9
UZ - Uzbekistan 9
BE - Belgio 8
CH - Svizzera 7
EG - Egitto 7
JM - Giamaica 7
JO - Giordania 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
PE - Perù 6
CR - Costa Rica 5
IR - Iran 5
RS - Serbia 5
SA - Arabia Saudita 5
AL - Albania 4
AU - Australia 4
AZ - Azerbaigian 4
DZ - Algeria 4
ET - Etiopia 4
KZ - Kazakistan 4
LB - Libano 4
NP - Nepal 4
PA - Panama 4
SN - Senegal 4
UY - Uruguay 4
BO - Bolivia 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
HN - Honduras 3
IL - Israele 3
KE - Kenya 3
KW - Kuwait 3
LV - Lettonia 3
MY - Malesia 3
NG - Nigeria 3
OM - Oman 3
RO - Romania 3
SY - Repubblica araba siriana 3
AO - Angola 2
BH - Bahrain 2
CG - Congo 2
LA - Repubblica Popolare Democratica del Laos 2
LU - Lussemburgo 2
LY - Libia 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BM - Bermuda 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
DK - Danimarca 1
EU - Europa 1
GF - Guiana Francese 1
GM - Gambi 1
GN - Guinea 1
Totale 14.114
Salva come PNG Salva come JPEG
Città #
Singapore 987
San Jose 809
Chandler 427
Moscow 425
Hong Kong 385
Ashburn 344
Beijing 326
Ho Chi Minh City 318
Naples 243
Hanoi 200
Santa Clara 189
The Dalles 147
Los Angeles 137
Amsterdam 135
Hefei 121
Jacksonville 113
Lauterbourg 110
Millbury 96
Munich 93
Princeton 90
Tokyo 88
Boston 85
New York 75
Nanjing 64
Napoli 62
Buffalo 57
Dallas 57
Houston 53
São Paulo 50
Haiphong 45
Da Nang 44
Wilmington 44
Warsaw 39
Helsinki 38
Frankfurt am Main 36
Pune 32
Woodbridge 31
Chicago 30
Ottawa 29
Orem 28
Seattle 28
Atlanta 27
Des Moines 27
Montreal 27
Redondo Beach 27
London 26
Turku 26
Cagliari 25
Rome 25
Seoul 24
Brooklyn 23
Stockholm 23
Mexico City 22
Nanchang 22
Denver 20
Hải Dương 19
Shanghai 19
Falls Church 18
Falkenstein 17
Kronberg 17
Lawrence 17
Rio de Janeiro 17
Shenyang 17
Johannesburg 16
Biên Hòa 15
Boardman 15
Council Bluffs 15
Jiaxing 15
Phoenix 15
Poplar 15
San Francisco 15
Tianjin 15
Düsseldorf 14
Ercolano 14
Nuremberg 14
Toronto 14
Capaccio 13
Manchester 13
Quito 13
Chennai 12
Dong Ket 12
Kunming 12
Norwalk 12
Thái Bình 12
Vienna 12
Can Tho 11
Hebei 11
Perugia 11
Washington 11
Baghdad 10
Kochi 10
Milan 10
Ninh Bình 10
Ankara 9
Changsha 9
Hyderabad 9
New Delhi 9
Acerra 8
Campinas 8
Columbus 8
Totale 7.642
Salva come PNG Salva come JPEG
Nome #
A novel ErbB2 epitope targeted by Human antitumor Immunoagents 183
A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab 178
Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model 173
Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics 170
Long-chain polyphosphates impair SARS-CoV-2 infection and replication 169
Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production 166
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2 164
A novel fully human Antitumor ImmunoRNase targeting ErbB2-positive tumors 159
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer 159
One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1 152
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology 148
Immunotoxins and ImmunoRNases 147
Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. 146
Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries 146
Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells 145
Novel Human Anti-ErbB2 Immunoagents 144
Novel Human Anti-ErbB2 Immunoagents 144
Effects of a human compact anti-ErbB2 antibody on prostate cancer 144
Novel human anti-Claudin 1 monoclonal antibodies inhibit HCV infection and may synergize with anti-SRB1 mAb. 143
A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells 143
Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma 142
Antitumor pancreatic-type RNases 140
Nuovi agenti con attività antitumorale nei tumori ErbB2-positivi 138
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. 136
Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing 136
Human Antitumor RNases and ImmunoRNases 135
Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling 134
Effects of protein RNase inhibitor and substrate on the quaternary structures of bovine seminal RNase 133
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. 133
The molecular basis for the production of an antitumor protein 133
New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC 132
Anti-ErbB2 human Immunoagents 132
Fusion protein comprising three binding domains to HER2 132
Interactions of spike‐rbd of sars‐cov‐2 and platelet factor 4: New insights in the etiopathogenesis of thrombosis 132
Novel combinations of human immunomodulatory mAbs lacking cardiotoxic effects for therapy of TNBC 132
Esiste la possibilità di ipotizzare un blocco dei recettori HER con immunoagenti senza effetti cardiotossici? 131
Evaluation of the antiproliferative effect of Bifidobacterium longum BB-536 in solid tumor cell lines, co-cultured with murine splenocytes 130
Immunomodulatory mabs as tools to investigate on cis-interaction of pd-1/pd-l1 on tumor cells and to set up methods for early screening of safe and potent combinatorial treatments 129
High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand 129
Fusion proteins 128
Thermodynamic stability of the two isoforms of bovine seminal ribonuclease. 128
The singular case of seminal RNase, a dimer with two quaternary conformations, inspected with Trypsin as a conformational probe 128
The antitumor action of seminal ribonuclease and its quaternary conformations 127
Anti-ErbB2 immunoagents 126
Anti-ErbB2 Human Immunoagents 126
Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays 125
8th International Meeting on Ribonucleases 124
Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. 123
T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells. 123
Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy 122
Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo 121
Anti-ErbB2 human immunoagents 121
A novel fully human antitumor ImmunoRNase targeting ErbB2-positive tumors 121
Trypsin sheds light on the singular case of seminal RNase, a dimer with two quaternary conformations. 120
Bovine Seminal RNase: an atypical member of the ribonuclease superfamily 120
A new human antitumor immunoreagent specific for ErbB2 119
A Novel Human Anti-tumor Dimeric ImmunoRNase 119
First and Second Generation Human anti-ErbB2 Immunoagents 118
Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells. 118
A novel ErbB2 epitope targeted by human antitumor immunoagents 116
HUMAN ANTI-FV ANTIBODY, THERAPEUTIC AND DIAGNOSTIC APPLICATIONS THEREOF 116
IMMUNORNASES AS ANTITUMOUR AGENTS 116
Human, Anti-ErbB2 Antitumor Immunoagents 116
A novel fully human antitumor ImmunoRNase resistant to the RNase inhibitor. 116
Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells 116
RANOLAZINE AT THE END OF TRASTUZUMAB THERAPY PREVENTS LEFT VENTRICULAR DYSFUNCTION: IN VITRO AND IN VIVO STUDY 116
A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy 115
Human anti-nucleolin recombinant immunoagent for cancer therapy 114
Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways 114
A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies 113
A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours. 112
Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents 111
Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of Ranolazine 111
Differential binding of human immunoagents and Herceptin to the ErbB2 receptor 109
Effects of a human compact anti-ErbB2 antibody on gastric cancer. 107
Evidences of CTLA-4 and PD-1 blocking agents-induced cardiotoxicity in cellular and preclinical models 107
A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent 106
Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation. 106
Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody 106
Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin 105
Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge 105
A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. 104
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2 103
Binding of human immunoagents and Herceptin to the ErbB2 receptor 103
NOVEL HUMAN ANTI-ErbB2 IMMUNOAGENTS 103
Inhibition of cardiomyocytes late I-Na with ranolazine blunts anthracyclines-cardiotoxicity in experimental models in vitro and in vivo 103
A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. 102
ImmunoRNases as antitumor agents 102
Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor 100
Speckle tracking echocardiography identifies cardiac dysfuntion induced by the anticancer ErbB2-blocker Lapatinib. 100
Novel human anti-ErbB2 immunoagents 99
DOXORUBICIN-INDUCED CARDIOTOXICITY IN MICE IS PREVENTED BY LATE INA INHIBITION WITH RANOLAZINE, WITH IMPROVEMENT IN HEART FUNCTION, FIBROSIS AND APOPTOSIS 99
Effects of three different anti-ErbB2 antibodies on prostate tumors 98
Methods and compositions relating to Anti-nucleolin recombinant immunoagents 98
A study of the Intracellular Routing of Cytotoxic Ribonucleases 97
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction 95
Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors 95
The antineoplastic ErbB2-antibody 2c4 produces left ventricular dysfunction in murine hearts. 93
A Novel Human Anti-FV mAb as a Potential Tool for Diagnostic and Coagulation Inhibitory Approaches 92
Filamentous Phage Display 92
Totale 12.450
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.843
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.843
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116 0 0 0 0 0 0 0 0 0 0 0 16
2021/2022704 4 4 2 3 12 16 22 34 122 48 194 243
2022/20231.010 124 77 31 86 123 118 5 85 171 116 57 17
2023/2024724 27 112 128 47 30 92 22 107 1 17 91 50
2024/20253.701 158 143 37 50 120 242 357 212 223 420 1.440 299
2025/20267.130 786 506 686 647 1.290 288 929 376 863 555 185 19
Totale 14.327